For patients with major depression, there was a clinically meaningful but not statistically significant improvement in the primary endpoint with 20-mg azetukalner. There were significant improvements ...

Good day, ladies and gentlemen, and welcome to this COMPASS Pathways update webinar. [Operator Instructions] As a reminder, this call is being recorded. I would now like to introduce your host for ...

Lipocine has initiated subject dosing in its two-arm, blinded, randomised Phase III trial of LPCN 1154 (oral brexanolone) for postpartum depression (PPD). This follows feedback from the Food and Drug ...

Shares of Relmada Therapeutics Inc. (NASDAQ:RLMD) were trading $2.15, down $2.01, or 48.3% on word of negative top-line results from the phase III study called Reliance-1, testing REL-1017 ...

Following a negative phase II/III study of an investigational treatment for major depressive disorder, Praxis Precision Medicines Inc. is dropping staff from the payroll and refocusing the company’s ...

Regulatory Recon: Sage Shares Soar After Postpartum Depression Drug Meets Phase III Goals FDA Approves Merck Drug to Prevent Post-Stem Cell Transplant Infections (9 November 2017) Welcome to ...

Despite missing the primary endpoint, the novel K V 7 potassium channel opener azetukalner showed benefit in major depressive disorder (MDD) in the phase II, proof-of-concept, randomized X-NOVA trial.